Phase 1 Gastro-oesophageal Reflux Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are willing and able to give written consent to participate in the study.
- Healthy men or women between 18 and 65 years of age.
- People with a body mass index (BMI) between 18.5 and 35.0.
- People and their partners who agree to follow the study's contraception requirements.
Who may not be able to join:
- Women who could become pregnant, unless they agree to use a highly effective form of contraception (with a failure rate of less than 1%) starting two weeks before receiving the study drug and continuing until the final study visit.
- Men whose partner could become pregnant, unless they agree to use contraception starting two weeks before receiving the study drug and continuing until the final study visit.
- People who have a history of, or currently have, a significant medical condition as defined by the study protocol (confirm with trial site).
- People who have a history of gastroesophageal reflux disease (GERD) or significant acid reflux.
- Women who are currently pregnant or breastfeeding, or anyone who plans to become pregnant or father a child at any point during the study period.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Erik Rein-Hedin, MD, CTC Clinical Trial Consultants AB
Phone: +32 470214020
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Measurement of pharmacokinetic profile of linprazan glurate and linaprazan (AUCinf); Measurement of pharmacokinetic profile of linprazan glurate and linaprazan (AUClast); Measurement of pharmacokinetic profile of linprazan glurate and linaprazan (Cmax); Measurement of pharmacokinetic profile of linprazan glurate and linaprazan (T1/2); Measurement of Cardiodynamic ECG (QTcF); Measurement of Cardiodynamic ECG (heart rate); Measurement of Cardiodynamic ECG (PR interval); Measurement of Cardiodynamic ECG (QRS interval); Measurement of Cardiodynamic ECG (placebo-corrected QTcF); Measurement of Card...
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.